Immuron Travelan record sales globally, Australia and USA
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Immuron Limited reports record sales of Travelan® globally, particularly in Australia and the USA, highlighting significant growth compared to the previous year. The company achieved substantial increases in sales figures for the financial year and the June quarter, with notable performance in the Australian market. The Chief Commercial Officer expressed optimism about continued growth in North America due to increased brand investment and distribution efforts. This filing serves as a results announcement detailing the sales performance of Immuron's Travelan® product.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Immuron
- IMM-529 pre-IND FDA filing
- Immuron Travelan sales continued strong growth
- Travelan to progress to Phase 3 Clinical Trials in the US
- Immuron achieves record Travelan sales
- Immuron achieves record half yearly Travelan sales
Later from Immuron
- Appendix 4E and Preliminary Final Report
- Immuron Plans Phase 2 Trial for IMM-529 following FDA review
- Trading Halt
- NMRC Reports Results for Campylobacter Clinical Study
- Immuron Announces Travelan Clinical Trial Update
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron